242 related articles for article (PubMed ID: 37446056)
1. GSK-3 Inhibitor Elraglusib Enhances Tumor-Infiltrating Immune Cell Activation in Tumor Biopsies and Synergizes with Anti-PD-L1 in a Murine Model of Colorectal Cancer.
Huntington KE; Louie AD; Srinivasan PR; Schorl C; Lu S; Silverberg D; Newhouse D; Wu Z; Zhou L; Borden BA; Giles FJ; Dooner M; Carneiro BA; El-Deiry WS
Int J Mol Sci; 2023 Jun; 24(13):. PubMed ID: 37446056
[TBL] [Abstract][Full Text] [Related]
2. GSK-3 inhibitor elraglusib enhances tumor-infiltrating immune cell activation in tumor biopsies and synergizes with anti-PD-L1 in a murine model of colorectal cancer.
Huntington KE; Louie AD; Srinivasan PR; Schorl C; Lu S; Silverberg D; Newhouse D; Wu Z; Zhou L; Borden BA; Giles FJ; Dooner M; Carneiro BA; El-Deiry WS
bioRxiv; 2023 Feb; ():. PubMed ID: 36798357
[TBL] [Abstract][Full Text] [Related]
3. Elraglusib (9-ING-41), a selective small-molecule inhibitor of glycogen synthase kinase-3 beta, reduces expression of immune checkpoint molecules PD-1, TIGIT and LAG-3 and enhances CD8
Shaw G; Cavalcante L; Giles FJ; Taylor A
J Hematol Oncol; 2022 Sep; 15(1):134. PubMed ID: 36104795
[TBL] [Abstract][Full Text] [Related]
4. Blocking IL-17A enhances tumor response to anti-PD-1 immunotherapy in microsatellite stable colorectal cancer.
Liu C; Liu R; Wang B; Lian J; Yao Y; Sun H; Zhang C; Fang L; Guan X; Shi J; Han S; Zhan F; Luo S; Yao Y; Zheng T; Zhang Y
J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33462141
[TBL] [Abstract][Full Text] [Related]
5. Augmented Antitumor Effect of Unripe
Lee EJ; Yang JH; Choi JG; Chung HS
Cells; 2022 Sep; 11(18):. PubMed ID: 36139451
[TBL] [Abstract][Full Text] [Related]
6. ILT4 inhibition prevents TAM- and dysfunctional T cell-mediated immunosuppression and enhances the efficacy of anti-PD-L1 therapy in NSCLC with EGFR activation.
Chen X; Gao A; Zhang F; Yang Z; Wang S; Fang Y; Li J; Wang J; Shi W; Wang L; Zheng Y; Sun Y
Theranostics; 2021; 11(7):3392-3416. PubMed ID: 33537094
[No Abstract] [Full Text] [Related]
7. Clinical significance of glycogen synthase kinase 3 (GSK-3) expression and tumor budding grade in colorectal cancer: Implications for targeted therapy.
Guil-Luna S; Rivas-Crespo A; Navarrete-Sirvent C; Mantrana A; Pera A; Mena-Osuna R; Toledano-Fonseca M; García-Ortíz MV; Villar C; Sánchez-Montero MT; Krueger J; Medina-Fernández FJ; De La Haba-Rodríguez J; Gómez-España A; Aranda E; Rudd CE; Rodríguez-Ariza A
Biomed Pharmacother; 2023 Nov; 167():115592. PubMed ID: 37778272
[TBL] [Abstract][Full Text] [Related]
8. Dual CTLA-4 and PD-L1 Blockade Inhibits Tumor Growth and Liver Metastasis in a Highly Aggressive Orthotopic Mouse Model of Colon Cancer.
Fiegle E; Doleschel D; Koletnik S; Rix A; Weiskirchen R; Borkham-Kamphorst E; Kiessling F; Lederle W
Neoplasia; 2019 Sep; 21(9):932-944. PubMed ID: 31412307
[TBL] [Abstract][Full Text] [Related]
9. Cytolytic activity correlates with the mutational burden and deregulated expression of immune checkpoints in colorectal cancer.
Zaravinos A; Roufas C; Nagara M; de Lucas Moreno B; Oblovatskaya M; Efstathiades C; Dimopoulos C; Ayiomamitis GD
J Exp Clin Cancer Res; 2019 Aug; 38(1):364. PubMed ID: 31429779
[TBL] [Abstract][Full Text] [Related]
10. Endostatin induces normalization of blood vessels in colorectal cancer and promotes infiltration of CD8+ T cells to improve anti-PD-L1 immunotherapy.
Chu XD; Bao H; Lin YJ; Chen RX; Zhang YR; Huang T; He JS; Huangfu SC; Pan YL; Ding H
Front Immunol; 2022; 13():965492. PubMed ID: 36389685
[TBL] [Abstract][Full Text] [Related]
11. Sulindac Modulates the Response of Proficient MMR Colorectal Cancer to Anti-PD-L1 Immunotherapy.
Yi B; Cheng H; Wyczechowska D; Yu Q; Li L; Ochoa AC; Riker AI; Xi Y
Mol Cancer Ther; 2021 Jul; 20(7):1295-1304. PubMed ID: 33879557
[TBL] [Abstract][Full Text] [Related]
12. Nutrient deprivation and hypoxia alter T cell immune checkpoint expression: potential impact for immunotherapy.
Davern M; Donlon NE; O'Connell F; Gaughan C; O'Donovan C; McGrath J; Sheppard AD; Hayes C; King R; Temperley H; MacLean M; Bulter C; Bhardwaj A; Moore J; Donohoe C; Ravi N; Conroy MJ; Reynolds JV; Lysaght J
J Cancer Res Clin Oncol; 2023 Jul; 149(8):5377-5395. PubMed ID: 36445478
[TBL] [Abstract][Full Text] [Related]
13. Simultaneous inhibition of two regulatory T-cell subsets enhanced Interleukin-15 efficacy in a prostate tumor model.
Yu P; Steel JC; Zhang M; Morris JC; Waitz R; Fasso M; Allison JP; Waldmann TA
Proc Natl Acad Sci U S A; 2012 Apr; 109(16):6187-92. PubMed ID: 22474386
[TBL] [Abstract][Full Text] [Related]
14. Targeting Interleukin-6 (IL-6) Sensitizes Anti-PD-L1 Treatment in a Colorectal Cancer Preclinical Model.
Li J; Xu J; Yan X; Jin K; Li W; Zhang R
Med Sci Monit; 2018 Aug; 24():5501-5508. PubMed ID: 30087314
[TBL] [Abstract][Full Text] [Related]
15. Fusobacterium nucleatum enhances the efficacy of PD-L1 blockade in colorectal cancer.
Gao Y; Bi D; Xie R; Li M; Guo J; Liu H; Guo X; Fang J; Ding T; Zhu H; Cao Y; Xing M; Zheng J; Xu Q; Xu Q; Wei Q; Qin H
Signal Transduct Target Ther; 2021 Nov; 6(1):398. PubMed ID: 34795206
[TBL] [Abstract][Full Text] [Related]
16. Co-inhibitor expression on tumor infiltrating and splenic lymphocytes after dual checkpoint inhibition in a microsatellite stable model of colorectal cancer.
Slovak RJ; Park HJ; Kamp WM; Ludwig JM; Kang I; Kim HS
Sci Rep; 2021 Mar; 11(1):6956. PubMed ID: 33772035
[TBL] [Abstract][Full Text] [Related]
17. Apatinib combined with PD-L1 blockade synergistically enhances antitumor immune responses and promotes HEV formation in gastric cancer.
Zhang Y; Wang F; Sun HR; Huang YK; Gao JP; Huang H
J Cancer Res Clin Oncol; 2021 Aug; 147(8):2209-2222. PubMed ID: 33891173
[TBL] [Abstract][Full Text] [Related]
18. Aldehyde Dehydrogenase 2 Mediates Alcohol-Induced Colorectal Cancer Immune Escape through Stabilizing PD-L1 Expression.
Zhang H; Xia Y; Wang F; Luo M; Yang K; Liang S; An S; Wu S; Yang C; Chen D; Xu M; Cai M; To KKW; Fu L
Adv Sci (Weinh); 2021 May; 8(10):2003404. PubMed ID: 34026438
[TBL] [Abstract][Full Text] [Related]
19. MicroRNA-124-3p suppresses PD-L1 expression and inhibits tumorigenesis of colorectal cancer cells via modulating STAT3 signaling.
Roshani Asl E; Rasmi Y; Baradaran B
J Cell Physiol; 2021 Oct; 236(10):7071-7087. PubMed ID: 33821473
[TBL] [Abstract][Full Text] [Related]
20. Rhamnazin Enhanced Anti-Tumor Efficacy of Anti-PD-1 Therapy for Lung Cancer in Mice through Inhibition of PD-L1 Expression.
Wang SS; Liu Y; Zhang XT; Yu DQ
Tohoku J Exp Med; 2023 May; 260(1):63-73. PubMed ID: 36823182
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
